GeoffroyPineau-Valencienne

Associé

Paris + 33.1.56.59.39.39

Contact

Partager

Geoffroy Pineau-Valencienne dispose d’une expérience étendue en capital-risque, private equity, fusions-acquisitions et droit boursier. Il accompagne principalement des entreprises à fort potentiel de croissance, cotées ou non, tout au long de leur développement, depuis leur phase d'amorçage jusqu'à leur industrialisation et au-delà, ainsi que leurs investisseurs industriels et financiers.

Les sociétés qu'il représente interviennent, principalement, dans les domaines des sciences de la vie (biotech, medtech), des nouvelles technologies (internet, logiciels) et de l’énergie (clean tech). Il dispose également d’une forte expérience transactionnelle à destination de ces sociétés dans le cadre de la conclusion de joint-ventures ou partenariats stratégiques, de recherche et développement de produits, de licence et distribution.

Geoffroy Pineau-Valencienne a récemment représenté des entreprises dans les domaines des technologies et des sciences de la vie, parmi lesquelles Amoéba, Amolyt Pharma, BonitaSoft, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Orega Biotech, Orphélia Pharma, Talend, Trace One, et Urban Canopée. Il a par ailleurs également représenté les investisseurs suivants : AbbVie, Alven, Andera, Balderton, BioMed, Bpifrance, Breega, CTI LifeSciences, Elaia, Fa-Dièse, Havenrock, HI Inov, Hil-Invest, Idinvest, Kurma, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Sofinnova Partners, Supernova, Ventech, Wellington, et Western Digital.

Il est en particulier intervenu dans le cadre de tours de financement, aussi bien du côté de la société émétrice que des investisseurs (dans le cadre des tours de financement notamment d'Alice&Bob, Amolyt Pharma, Alédia, CorWave, Domain Therapeutics, Inotrem, Masteos, MadBox, May Health, Mutabilis, Lendix, OpsMill, UpMem, UroMems, TriCares et Vulkam), des opérations de fusions-acquisitions de sociétés cotées ou non (notamment l’acquisition d'Amolyt Pharma par AstraZeneca pour 1.05 milliards de dollars, l’acquisition de Pipplet par ETS Global, les cessions d'Alizé Pharma à Millendo, de Mathym à Baikowski, d'Endocontrol à Canady Life Sciences, et de SoCloz à Savoye ; et la fusion (reverse merger) de Genticel avec Genkyotex). Il est également intervenu sur plusieurs introductions en bourse et placements privés (notamment, celles d’Amoéba, Genticel et Enertime sur le marché Euronext Growth ou le marché réglementé d’Euronext à Paris, et de Cellectis et Talend sur le Nasdaq aux Etats-Unis).

Expérience

  • Seventure and Entrepreneur Venture Gestion invest €6 million in IzicapJones Day advised Seventure Partners and Entrepreneur Venture Gestion in connection with the €6 million (US$6.9 million) Series A round of financing of Izicap, a provider of customer relationship marketing tools through consumers bank cards and existing payment terminals.
  • Wellington Partners, Andera Partners, and BioMed Partners invest €22 million in TRiCaresJones Day represented Wellington Partners, Andera Partners, and BioMed Partners in connection with the €22 million (US$25.4 million) Series B financing round of TRiCares SAS, a French medtech company pioneer in the field of minimally invasive treatment of tricuspid regurgitation.
  • Talend completes $188.4 million secondary offering of American Depositary Shares on NASDAQ by Selling ShareholdersJones Day represented Talend SA, a French global leader in cloud and big data integration software, in connection with the $188.4 million secondary public offering of American Depositary (each representing one of its ordinary shares) on NASDAQ, by investment funds affiliated with Silver Lake Sumeru and investment funds affiliated with Balderton Capital.
  • Alizé Pharma SAS acquired by Millendo Therapeutics, Inc.Jones Day advised Alizé Pharma SAS, a French clinical-stage biotech private company, in connection with its sale in a stock-for-stock transaction to Millendo Therapeutics, Inc., a U.S. clinical-stage biotech private company focused on developing novel treatments for endocrine diseases.
  • Talend completes public offering of American Depositary Shares on NASDAQJones Day represented Talend SA, a global leader in cloud and big data integration software, in connection with its underwritten public offering of American Depositary Shares on NASDAQ by funds affiliated with Silver Lake Sumeru and Balderton Capital.
  • New Alpha invests in WiztopicJones Day represented New Alpha Asset Management in connection with its investment in Wiztopic SAS, a publisher of an SaaS solution dedicated to corporate and financial communication executives.
  • Western Digital invests in UPMEMJones Day represented Western Digital, a leading provider of storage technologies and solutions that enable people to create, leverage, experience, and preserve data, in connection with its purchase of Series A Preferred Stock in a private placement by UPMEM, a fabless semiconductor company developing next generation hardware solutions for data intensive applications in the datacenter.
  • Talend completes follow-on public offering on NASDAQ by certain of its main shareholdersJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with the follow-on public offering of American Depositary Shares (ADSs) on NASDAQ by certain of its main shareholders.
  • Hi Inov invests InterCloudJones Day represented Hi Inov in connection with its investment in InterCloud, a France-based provider of enterprise cloud delivery solutions.
  • Reverse sale of Genticel to GenKyoTex SA to become GenkyotexJones Day advised Genticel SA in connection with its reverse sale to the shareholders of GenKyoTex who received approximately 80 percent of the share capital of Genticel in remuneration of their contribution of GenKyoTex shares to Genticel.
  • Wellington Partners, Bpifrance, CITA Investissement, CEA Investissement, and b-to-v Partners invest in UroMemsJones Day advised Wellington Partners, Bpifrance, CITA Investissement, CEA Investissement, and b-to-v Partners AG in connection with a €12 million ($12.7 million) private placement in UroMems, an innovative medtech company developing an active medical implantable device for treatment of urinary incontinence.
  • Apax and Europe Snacks obtain financing for acquisition of Kolak Snack FoodsJones Day represented Apax Partners Midmarket SAS and Europe Snacks in connection with the financing of the acquisition by Europe Snacks of Kolak Snack Foods and the refinancing of its debt.
  • Permira Debt Managers provides unitranche financing for acquisition of I@D groupJones Day represented Permira Debt Managers Limited in connection with its unitranche financing for the acquisition of the I@D group, a services platform dedicated to the first network of independent real estate agents in France.
  • Talend completes IPO of American Depositary Shares on NASDAQJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with its issuance of $94.5 million of American Depositary Shares in an initial public offering on NASDAQ.
  • Enertime completes IPO on Alternext market of Euronext in ParisJones Day advised Enertime SAS, an innovating Energy solutions developer, along with Portzamparc Société de Bourse, as listing sponsor, in connection with the proposed initial public offering of Enertime on the Alternext market of Euronext in Paris.
  • Criteo acquires Monsieur DriveJones Day advised Criteo S.A., a French technology company listed on the NASDAQ specializing in performance display advertising, in connection with its acquisition of Monsieur Drive, a French company which operates and develops digital advertising solutions for consumer brands.
  • Amoéba completes €14.7 million private placement of new sharesJones Day represented Amoéba SAS, a developer of sustainable organic biocide capable of mitigating bacterial risk in water systems, in connection with the €14.7 million (US$16.5 million) private placement of new shares to European and American investors.
    •

    September 18-20, 2023 Speaking Engagements

    Jones Day lawyers to attend IPEM 2023

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.